medicines

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed…

2 days ago

Medkart Launches India's First Tool to Find Substitute Medicine and Compare Prices, Transforming Access to Affordable Healthcare

In a significant stride towards affordable healthcare, Medkart Pharmacy has unveiled India's first comprehensive online platform dedicated to comparing your…

2 days ago

Government Push for Generic Drugs Finds Digital Ally in New Healthcare Portal

India's healthcare landscape is undergoing a significant transformation, led by national initiatives like Ayushman Bharat and the Jan Aushadhi Yojana.…

3 days ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

5 days ago

Medkart Champions Generic Drug Quality Amid Rising Consumer Concerns

With growing scrutiny around the quality and reliability of generic medicines in India, Medkart, Gujarat’s largest generic-first pharmacy chain, is…

6 days ago

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional…

3 weeks ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

1 month ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

September 03, 2025 21:47 ET  | Source: Mesoblast Limited NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

2 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

September 02, 2025 21:33 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…

2 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…

2 months ago